@article{834cbf415ebc4a7282ef6ead05a88cba,
title = "The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma",
abstract = "Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72% of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiological function in brain development, a soluble splice variant of EPHA7 (EPHA7TR) interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7TR protein produces antitumor effects against xenografted human lymphomas. Further, by fusing EPHA7 TR to the anti-CD20 antibody (rituximab) we can directly target this tumor suppressor to lymphomas in vivo. Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7TR as tumor suppressor with immediate therapeutic potential.",
author = "Elisa Oricchio and Gouri Nanjangud and Wolfe, {Andrew L.} and Schatz, {Jonathan H.} and Mavrakis, {Konstantinos J.} and Man Jiang and Xiaoping Liu and Joanne Bruno and Adriana Heguy and Olshen, {Adam B.} and Socci, {Nicholas D.} and Julie Teruya-Feldstein and Frances Weis-Garcia and Wayne Tam and Rita Shaknovich and Ari Melnick and Himanen, {Juha P.} and Chaganti, {R. S.K.} and Wendel, {Hans Guido}",
note = "Funding Information: We thank L. Pasqualucci, E. Papapetrou, S.L. Morrison, and M. Teitell for reagents; several MSK core facilities, including the Research Animal Facility, A. Viale of the Genomics Core, Elisa deStanchina of the Antitumor Assessment Core, A. Lash of the Computational Biology Core, Katy Huberman of the Geoffrey Beene Translational Oncology Core Facility, Aleksey V. Kamenshchikov of the Monoclonal Antibody Core Facility, and Irina Linkov of the Pathology Core. This work is supported by grants from the NCI (R01-CA142798-01), a P30 supplemental award from the NCI and the AIDS Malignancy Consortium (AMC) (H.G.-W.), the Leukemia Research Foundation (H.G.-W.), the Louis V. Gerstner Foundation (H.G.-W.), the WLBH Foundation (H.G.-W.), the Society of MSKCC (H.G.-W.), the Starr Cancer Consortium grant I4-A410 (H.G.-W. and J.H.), NIH MSTP grant GM07739 (J.B.), NIH-K08 CA127353 (R.S), the ASCO Cancer Foundation (J.H.S.), LLS TRP (R.S.), LLS SCOR S 7032-04 (A.M.), NCI R01 CA104348 (A.M.) LLS scholar (A.M.), Burroughs Wellcome Clinical Translational Scientist (A.M.), Cancer Center Support Grant P30- CA008748 (F.W.-G.) and a SCOR grant from The Leukemia and Lymphoma Society (R.S.K.C.). ",
year = "2011",
month = oct,
day = "28",
doi = "10.1016/j.cell.2011.09.035",
language = "English (US)",
volume = "147",
pages = "554--564",
journal = "Cell",
issn = "0092-8674",
publisher = "Elsevier B.V.",
number = "3",
}